- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
PharmaResearch Receives FDA Clearance for Phase 1 Trial of Nano Anticancer Drug
The new drug candidate, PRD-101, utilizes the company's proprietary DNA optimizing technology.
Published on Feb. 6, 2026
Got story updates? Submit your updates here. ›
PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States. PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology).
Why it matters
The development of PRD-101 represents a significant advancement in cancer treatment, as traditional anticancer drugs often face limitations due to high toxicity. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy.
The details
The drug leverages the company's nucleotide-based Advanced DOT® drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics. The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101.
- PharmaResearch announced the FDA clearance on February 6, 2026.
The players
PharmaResearch Co., Ltd.
A pharmaceutical company that develops innovative cancer treatments, including the nano anticancer drug PRD-101.
University of California Irvine (UCI)
Researchers from UCI have collaborated with PharmaResearch on the development of PRD-101.
U.S. National Cancer Institute (NCL)
An organization that has provided support for the development of PRD-101.
What’s next
The Phase 1 clinical trial of PRD-101 is expected to begin enrollment in the coming months.
The takeaway
The development of PRD-101 represents a significant advancement in cancer treatment, as the nano anticancer drug aims to address the limitations of traditional therapies by utilizing PharmaResearch's proprietary DNA optimizing technology.
